Financials data is unavailable for this security.
View more
Year on year HOB Biotech Group Corp Ltd grew revenues 23.10% from 320.39m to 394.41m while net income improved 13.64% from 41.65m to 47.33m.
Gross margin | 61.87% |
---|---|
Net profit margin | 8.79% |
Operating margin | 10.62% |
Return on assets | 3.60% |
---|---|
Return on equity | 4.39% |
Return on investment | 4.33% |
More ▼
Cash flow in CNYView more
In 2023, HOB Biotech Group Corp Ltd increased its cash reserves by 6.63%, or 10.16m. The company earned 102.69m from its operations for a Cash Flow Margin of 26.04%. In addition the company used 39.55m on investing activities and also paid 53.12m in financing cash flows.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 12.95 |
---|---|
Tangible book value per share | 12.76 |
More ▼
Balance sheet in CNYView more
Current ratio | 1.53 |
---|---|
Quick ratio | 0.9438 |
Total debt/total equity | 0.1353 |
---|---|
Total debt/total capital | 0.1192 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 33.33% and 13.64%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Medical Equipment & Supplies industry pay a dividend. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
Div yield(5 year avg) | -- |
---|---|
Div growth rate (5 year) | -- |
Payout ratio (TTM) | 71.16% |
EPS growth(5 years) | -2.43 |
---|---|
EPS (TTM) vs TTM 1 year ago | -1.15 |
More ▼